News and Events
Stay up to date with news and events
Astrocytes: The new star in HD research?
The most obvious changes related to Huntington’s disease (HD) happen to neurons, the nervous system’s messenger cells that send and receive information throughout the brain…
Hunting for balance: how the huntingtin protein compensates in HD
A group led by Dr. Sandrine Humbert from the French National Institute for Health and Medical Research published new work in the prestigious journal Science….
Roche Phase II GENERATION HD2 study underway
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
Map-HD Registry has the first 100 participants!
Thank you to each and every person who signed up! Read the full article here.